Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Lawrence, Rice"'
Autor:
Lawrence Rice, Eric Salazar
Publikováno v:
Rossi's Principles of Transfusion Medicine. :188-193
Autor:
Ethan Burns, Kartik Anand, Gonzalo Acosta, Malcolm Irani, Betty Chung, Abhishek Maiti, Ibrahim Ibrahim, Lawrence Rice
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Autosplenectomy (AS) is a known complication of diseases such as sickle cell anemia, celiac disease, and inflammatory bowel disease. We report the first known case of AS due to paroxysmal nocturnal hemoglobinuria (PNH). A 24-year-old Caucasian male h
Externí odkaz:
https://doaj.org/article/c70cf100456a4197aca2c76098b367d8
Autor:
Faaria Gowani, Bonnie Phillips, Christopher Leveque, Brian Castillo, Jian Chen, Wayne Chandler, Lawrence Rice, Eric Salazar
Publikováno v:
Laboratory Medicine. 53:e91-e94
Acquired von Willebrand disease (avWD) arises because of mechanisms that destroy, decrease, absorb, or clear von Willebrand factor (vWF). A 59-year-old man presented with a 3-year history of recurrent gastrointestinal bleeding. Laboratory workup reve
Publikováno v:
Annals of Internal Medicine: Clinical Cases. 1
Autor:
Lawrence Rice
Publikováno v:
Biologics: Targets & Therapy, Vol 2009, Iss default, Pp 151-157 (2009)
Lawrence RiceWeill Cornell Medical College, The Methodist Hospital, Houston, Texas, USAAbstract: Immune thrombocytopenic purpura (ITP) is a relatively common autoimmune disorder in which antibodies are produced to circulating platelets. Symptoms can
Externí odkaz:
https://doaj.org/article/6c28fca0d9f74d4d9876a2b6c8052885
Publikováno v:
Cytometry Part B: Clinical Cytometry. 100:240-242
Publikováno v:
Journal of Pharmacy Practice and Research. 49:130-134
Autor:
Hanns-Christian Gunga, Lawrence Rice
Publikováno v:
Acta Physiologica.
Autor:
Godsfavor Umoru, Shilpan S. Shah, Sai Ravi Pingali, Kartik Anand, Siddhartha Ganguly, Carlo Guerrero, Cesar Gentille, Lawrence Rice, Ethan Burns, Jenny H. Petkova, Ryan B. Kieser, Joe Ensor
Publikováno v:
Blood. 138:4740-4740
Background Daratumumab-based treatment regimens for MM have improved outcomes for both transplant-eligible and ineligible patients. As a result, patients are receiving longer exposure to this CD38 targeting monoclonal antibody. Adverse events (AE) in